Executive Summary / Key Takeaways
- VITAS has successfully navigated its Florida Medicare Cap crisis by strategically shifting to short-stay hospital admissions, sacrificing near-term margins to eliminate a $27.2 million billing limitation and positioning for margin recovery in 2026 as patient mix rebalances.
- Roto-Rooter faces structural headwinds from private equity competition and Google algorithm changes that have increased customer acquisition costs by 50%, but the company's 90-year-old brand and operational countermeasures should stabilize margins by late 2026.
- Chemed's fortress balance sheet—zero debt, $404 million in available credit, and $325 million in annual free cash flow—provides substantial downside protection while management executes operational turnarounds in both segments.
- 2026 guidance implies 8-12% adjusted EPS growth weighted to the second half, but execution risks remain elevated: VITAS must carefully calibrate patient mix to avoid renewed cap issues, while Roto-Rooter's lead generation recovery remains unproven.
Setting the Scene: A Tale of Two Turnarounds
Chemed Corporation, founded in 1970 as a Delaware corporation, operates two businesses that share little more than a common owner. VITAS, which generated $1.63 billion in 2025 revenue, is one of the nation's largest hospice providers, delivering end-of-life care to over 22,000 patients daily through an interdisciplinary network of physicians, nurses, and social workers. Roto-Rooter, with $900 million in revenue, provides plumbing and drain cleaning services through a hybrid model of company-owned branches and franchisees, leveraging trademarks that have been in continuous use since 1935. This unusual pairing creates a diversified cash flow stream that has supported 218 consecutive quarterly dividends, but both segments now face distinct operational challenges that converged in 2025 to compress consolidated gross margins from 35.1% to 32.5%.
The hospice industry operates under Medicare's strict reimbursement caps, creating a permanent tension between patient mix and profitability. VITAS derives over 95% of revenue from Medicare and Medicaid, making it exquisitely sensitive to regulatory changes and cap calculations. The Medicare Cap limits average per-admission payments, penalizing providers whose patient population lives too long relative to national averages. This structural constraint has historically favored VITAS's ability to manage patient mix, but the 2025 cap year exposed a vulnerability: Florida's reimbursement rates increased 200 basis points faster than the national average, creating an $18.9 million billing limitation that threatened to escalate further.
Meanwhile, Roto-Rooter competes in a fragmented $20 billion plumbing services market against thousands of local operators and a new breed of private equity-backed consolidators. The business model relies on brand recognition and local presence to generate service calls, with Google (GOOGL) search visibility serving as the primary lead generation engine. When Google altered its algorithms in late 2024, Roto-Rooter's map appearance rate collapsed from 72% to 24% nationwide, forcing a costly pivot from free organic leads to paid search that now represents 60-65% of all leads. This shift increased customer acquisition costs from $0 to $150-180 per job, directly compressing EBITDA margins by 477 basis points in Q4 2025.
Technology, Products, and Strategic Differentiation
VITAS's competitive moat rests on its ability to deliver complex palliative care at scale while navigating Medicare's regulatory labyrinth. The company's "Difference Maker Program," which paid $39.2 million in retention bonuses since July 2022, addresses the industry-wide shortage of licensed healthcare workers by ensuring clinical continuity. The significance of this program lies in the fact that hospice care quality depends on stable, experienced teams who can manage pain, coordinate family support, and document medical necessity to withstand audits. While competitors like Enhabit Home Health & Hospice (EHAB) struggle with post-spin-off operational disruptions and negative net margins, VITAS maintains 21.7% EBITDA margins even while admitting a higher percentage of short-stay patients.
The strategic differentiation extends to VITAS's geographic expansion strategy. The company secured four Certificate of Need (CON) awards in Florida over two years, including Manatee County in December 2025. These new programs provide dual benefits: they capture underserved markets with 3,000+ Medicare hospice patients and create additional Medicare Cap cushion by diluting the impact of longer-stay patients. The Marion County program, opened in May 2025, reached 75 average daily census by September and is projected to double by year-end 2026. This measured expansion contrasts with The Pennant Group's (PNTG) decentralized affiliate model, which sacrifices standardization for rural penetration. VITAS's centralized approach enables materially faster scalability and consistent margin performance across markets.
Roto-Rooter's moat is its brand, but the 90-year-old trademark is being stress-tested by digital disruption. Private equity competitors like those backed by HVAC consolidators have entered plumbing with a "loss-leader" strategy, offering $77 drain cleanings to acquire customers for higher-margin HVAC services. This trend permanently resets price expectations for commodity services while PE firms absorb losses through cross-subsidization. Roto-Rooter refuses to engage in this "race to the bottom," instead focusing on add-on services like water restoration and excavation that grew 6.9% and 4.8% respectively in 2025. These services, which originate from initial drain cleaning calls, generate higher margins and are less susceptible to PE competition because they require specialized equipment and expertise that franchisees lack.
The company's response to Google's algorithm changes reveals strategic adaptability. By contracting a new SEO provider in December 2025 and centralizing water restoration billing, Roto-Rooter acknowledges that local branch autonomy must yield to centralized expertise in digital marketing and complex insurance negotiations. This shift reverses decades of decentralized operations, requiring cultural change and IT investment. The early results show promise: collection experience improved in early 2026, and management expects a $4-6 million tailwind from better water restoration collections in the second half of 2026.
Financial Performance & Segment Dynamics: Evidence of Strategic Execution
VITAS's 2025 financial performance tells a story of deliberate trade-offs. Revenue grew 6.5% to $1.63 billion, driven by a 5.2% increase in days-of-care and a 3.4% Medicare rate increase. However, adjusted EBITDA declined 4.8% to $271.9 million, and margins compressed 240 basis points to 16.7%. This deterioration was a strategic choice: admitting more short-stay hospital patients reduces per-patient revenue and margins but provides Medicare Cap cushion. The Florida cap position improved by nearly $25 million, and management is confident the 2025 problem is resolved.
The quarterly progression reveals the tactical execution. Q1 2025 showed strong 15.1% revenue growth and 17.2% EBITDA margins as the Covington Health acquisition contributed 3-4% to results. By Q4, revenue growth slowed to 1.9% and margins fell to 21.7% (excluding cap impact) as the short-stay strategy peaked. This sequential change signals the limit of how far VITAS can push the strategy without damaging profitability. Management's mid-January 2026 decision to rebalance admissions toward longer-stay patients indicates recognition that the optimal cap cushion has been achieved.
Roto-Rooter's 2025 results demonstrate the cost of digital disruption. Revenue was essentially flat at $900 million, but adjusted EBITDA plunged 13.6% to $204.7 million, with margins collapsing from 26.3% to 22.8%. The culprits were precise: a $5.3 million increase in casualty insurance expense and a 41.8% surge in water restoration write-offs as AI-driven insurance scrutiny rejected line-item charges. The Q4 margin of 21.5% represented a 477 basis point decline, with $4 million of the shortfall attributable directly to increased write-offs.
The segment dynamics highlight a critical difference in competitive exposure. VITAS's margin pressure was self-inflicted and reversible; Roto-Rooter's stems from external structural changes. Addus HomeCare (ADUS), with its personal care focus, faces similar labor cost inflation but benefits from Medicaid rate increases that VITAS's Medicare-dominant model lacks. EHAB's negative profit margins and 89% debt-to-equity ratio make its hospice operations structurally disadvantaged compared to VITAS's 25.3% ROE. PNTG's 25.0 EV/EBITDA multiple reflects its growth premium but masks inferior 6.25% operating margins that VITAS's scale and expertise render unattainable for smaller players.
Outlook, Management Guidance, and Execution Risk
Management's 2026 guidance frames the year as a transition for both segments, but the underlying assumptions reveal confidence in strategic execution. VITAS is projected to grow revenue 5.5-6.5% with EBITDA margins of 17.5-18% prior to Medicare Cap impacts. The $9.5 million estimated cap liability for 2026 represents a 65% reduction from 2025's $27.2 million, with management explicitly stating there is no Medicare Cap billing limitation related to the Florida program. This development removes a significant overhang on the segment's earnings power and validates the short-stay strategy's effectiveness.
The guidance's second-half weighting—55% of adjusted EBITDA projected for H2—reflects the patient mix rebalancing timeline. As VITAS shifts back toward longer-stay admissions, revenue per patient and margins should improve sequentially. The Marion and Pasco County programs, admitting 40-50 new patients monthly, will mature and contribute more fully in H2. This trajectory is more sustainable than the 2023-2024 growth rates that were likely higher than what was sustainable for the long term due to the Medicare cap.
Roto-Rooter's 3-3.5% revenue growth target and 22.5-23% EBITDA margin outlook depend on three specific drivers: improved lead volume from SEO initiatives, commercial sales force expansion, and water restoration collection improvements providing a $5.5 million tailwind. The commercial business manager program, which drove 10% higher revenue growth in branches with dedicated resources, will expand in 2026. This matters because commercial customers generate higher average tickets and repeat business, reducing dependence on volatile residential leads.
Execution risks are material and identifiable. For VITAS, the risk is overcorrection—if the rebalancing toward longer-stay patients is too aggressive, the Florida cap cushion could erode, creating a 2027 problem. Management must thread the needle between margin optimization and cap compliance. For Roto-Rooter, the SEO improvements are unproven, and PE competitors may intensify drain cleaning price wars. The water restoration collection improvements require centralizing functions that have been branch-based for decades, creating change management risk.
Risks and Asymmetries: What Could Break the Thesis
The Medicare Cap remains the primary risk to VITAS's earnings power, but the mechanism has shifted. The immediate Florida crisis is resolved, but national hospice policy faces mounting pressure to control costs. If CMS reduces reimbursement rates or tightens cap calculations, VITAS's 95% Medicare/Medicaid exposure creates asymmetric downside. A 2% rate cut would reduce revenue by $32 million with no offsetting cost reduction, given labor represents the majority of expenses. This risk is amplified by the demographic reality that aging baby boomers will increase hospice demand, potentially triggering more aggressive cost controls.
Labor cost inflation presents a structural challenge. The $39.2 million spent on retention bonuses since 2022 indicates VITAS operates in a seller's market for licensed nurses. While the Difference Maker Program has stabilized staffing, competitors like ADUS and EHAB face identical pressures, suggesting industry-wide margin compression. The core question for Chemed is whether VITAS can maintain its premium service model without pricing power to offset wage inflation.
Roto-Rooter's digital disruption risk is more acute. If Google's algorithm changes permanently reduce organic visibility, customer acquisition costs could rise another 20-30%, making the 25-26% long-term EBITDA margin target unattainable. PE competitors have different investment horizons and cross-subsidization strategies that Roto-Rooter cannot match without sacrificing its premium brand positioning. The risk is that plumbing services become commoditized, with price becoming the primary purchase criterion.
Cybersecurity represents a latent risk. The October 2025 breach, while contained, exposed vulnerability through a third-party vendor. In healthcare, PHI breaches carry regulatory penalties and reputational damage that could impact VITAS's referral relationships. The $500,000 deductible and insurance coverage mitigate financial impact, but repeated incidents could trigger a Corporate Integrity Agreement renewal, increasing compliance costs.
Valuation Context: Pricing for Execution Certainty
At $377.74 per share, Chemed trades at 20.6x trailing earnings and 16.4x free cash flow, a modest premium to healthcare services peers but a discount to its historical multiple when growth was more robust. The EV/EBITDA of 13.4x sits between EHAB's 13.6x and PNTG's 25.0x, reflecting market skepticism about Roto-Rooter's structural challenges offsetting VITAS's recovery.
The valuation metrics reveal investor focus on quality over growth. Chemed's 25.3% ROE and 13.4% ROA significantly exceed ADUS's 9.3% and 6.1%, respectively, demonstrating superior capital allocation. The 0.61% dividend yield, while modest, is supported by a 12% payout ratio and 218 consecutive quarters, indicating dividend security. The zero debt position and $404 million in available credit provide strategic optionality for acquisitions or accelerated buybacks.
The trajectory of margin recovery is the primary driver for valuation. If VITAS achieves the guided 17.5-18% EBITDA margins and Roto-Rooter reaches 22.5-23%, 2026 adjusted EPS of $23.25-24.25 would represent 8-12% growth. At a market-average 18x earnings multiple, the stock would trade at $418-437, offering 11-16% upside. However, if Roto-Rooter's structural headwinds persist and VITAS cap management falters, flat earnings could justify a multiple compression to 15x, implying downside to $350.
Conclusion: Two Turnarounds, One Pristine Balance Sheet
Chemed's investment thesis hinges on the successful execution of two distinct turnarounds. VITAS must convert its Medicare Cap victory into sustainable margin expansion by carefully calibrating patient mix, while Roto-Rooter must prove its brand and operational adjustments can offset digital disruption and PE competition. The company's pristine balance sheet and disciplined capital allocation provide a floor, but the ceiling depends on management's ability to navigate these operational challenges.
The clarity of the path forward is a key attribute of this thesis. VITAS's cap issue is quantifiable and appears resolved, with 2026 guidance providing specific milestones. Roto-Rooter's challenges are equally clear, with management implementing targeted solutions rather than hoping for competitive rationality. The asymmetry lies in the timing: VITAS's recovery should materialize in H2 2026, while Roto-Rooter's improvements may take longer to prove.
For investors, the critical variables are VITAS's patient mix rebalancing and Roto-Rooter's lead generation recovery. If both execute, Chemed offers double-digit earnings growth at a reasonable multiple. If either falters, the diversified structure and strong cash generation limit downside. The stock's current valuation reflects cautious optimism—neither pricing in perfection nor discounting distress. In an environment where many healthcare services companies face existential reimbursement pressures, Chemed's self-inflicted and solvable problems represent a relative safe harbor with a clear catalyst for improvement.
